Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02281357 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
NCT02281357 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 140 participants.
The verdict
NCT02281357, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
Study Summary
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid dependent Asthma.
Interventions
- OTHER Placebo
- BIOLOGICAL Tralokinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2015-02-19 |
| Est. Completion | 2017-09-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02281357
The ClinicalTrials.gov registry entry for NCT02281357 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02281357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02281357 about?
NCT02281357 is a clinical study titled "Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma". A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid dependent Asthma.
What is the current status of trial NCT02281357?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2015-02-19. Estimated completion is 2017-09-07.
What interventions are being tested in trial NCT02281357?
The interventions under investigation include: Placebo (OTHER), Tralokinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02281357?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.